Support Alert

Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a letter to healthcare professionals: Esmya (ulipristal acetate) for uterine fibroids: monitor liver function in current and recent users; do not initiate treatment in new users or those between treatment courses. 


Some of our content, including support alerts, is only available to RPS members. 

Log in

Find out more about membership of the Society

Loading...
Return To Top